Apoptosis mediated by the proapoptotic BCL-2 family members BCL-2-associated X-protein (BAX) and BCL-2 antagonist/killer (BAK) is part of the antiviral response at the cellular level to limit virus replication. Viruses, in turn, have evolved to encode antiapoptotic BCL-2 homologs (v-BCL-2s) to prevent the premature death of the infected host cell to sustain virus replication. These same v-BCL-2 proteins cooperate with loss of retinoblastoma protein and p53 tumor suppressor function, by inactivating the BAX and BAK apoptotic pathway to promote epithelial solid tumor growth and resistance to chemotherapy. Analogously to infected cells, failure of apoptosis in tumors permits the survival of abnormal, damaged cells displaying chromosome instability that may further promote tumor progression. Thus, both infected cells and tumor cells require inhibition of the apoptotic host defense mechanism, the insights from which can be exploited for therapy development.
Introduction
As a postdoctoral fellow in Bruce Stillman's laboratory at Cold Spring Harbor Laboratory, I was given the project to determine the function of a putative novel oncogene, E1B 19K, encoded by the DNA tumor virus adenovirus. It was determined that the left end of the viral genome, the E1 region, encoded the oncogenic activity of the virus.
1,2 Within E1, E1A was discovered to be a transcription regulator that potently stimulated cell proliferation. These activities would soon be linked to the interaction of E1A with the retinoblastoma tumor suppressor protein (RB) and its relatives, activation of E2Fs, and progression through the G1/S cell cycle transition. The other region within E1, E1B, encoded two distinct proteins from overlapping reading frames, E1B 55K and E1B 19K. E1B 55K was known to interact with the p53 tumor antigen that would soon be recognized as a tumor suppressor required for cell cycle arrest in response to DNA damage and stress. In contrast, the function of the E1B 19K protein was not known. E1B 19K had no homologs outside of adenoviruses and its interaction partners in cells were not identified. Furthermore, any function of the E1B 19K protein associated with oncogenesis was unknown, and its function in the replication cycle of the virus had also not been determined. Our initial approach was to use viral E1B 19K mutant viruses to establish the function of the protein in productively infected cells where the life cycle of the virus was well characterized.
We, along with others, simultaneously discovered that in contrast to the wild-type virus, infection with E1B 19K mutant viruses caused the degradation of the host cell and viral DNA; a rather obscure and uninformative phenotype at the time. [3] [4] [5] [6] I realized that induction of DNA fragmentation was indicative of induction of programmed cell death by apoptosis, a virtually unknown and poorly characterized process in the 1980s. 7 Nonetheless, making this connection suggested that the E1B 19K protein might be an inhibitor of apoptosis in response to the expression of another viral gene. Indeed, adenovirus infection-induced apoptosis mapped to E1A, suggesting that E1B 19K was required to sustain the viability of the infected host cell in response to E1A expression to prevent premature termination of virus replication. 8 How E1A induced and E1B 19K inhibited apoptosis, and the means by which this could possibly be linked to oncogenesis, remained to be determined.
In vitro immortalization of rodent kidney epithelial cells is used to assay the oncogenic function of viral and cellular oncogenes, for which two or more cooperating genes are required for focus formation. 9 Remarkably, E1A alone in this assay induces foci that regress by apoptosis, which is suppressed by E1B 19K and E1B 55K. 10, 11 Similar findings were also reported for the cellular oncogene c-myc. 12, 13 This suggested, that just as in virus infected cells, E1A function was essential but cytotoxic, the latter of which required suppression of apoptosis. The capacity for either E1B 19K and E1B 55K to alleviate the toxicity of E1A suggested that both E1B proteins had antiapoptotic activity.
The involvement of E1B 55K protein in the suppression of apoptosis induced by E1A suggested a possible role for p53. The Oren laboratory 14 reported the proapoptotic function of p53, which paved the way for the revelation that E1A induced p53 accumulation and p53-mediated apoptosis. 15, 16 Importantly, this p53-mediated apoptosis was dependent on the transcription regulation function of p53, 17 and was responsible for suppressing the process of epithelial immortalization by E1A. 15 Thus, apoptosis emerged as an important tumor suppression mechanism in response to oncogene activation.
Unlike E1B 55K whose activity was p53-specific, E1B 19K blocked apoptosis not only by p53 but by other diverse stimuli including death receptor signaling, suggesting that it was a general apoptosis inhibitor. 11 At the time the only other antiapoptotic protein known was B-cell CLL/lymphoma 2 (BCL-2), which was identified as an oncoprotein in human B-cell follicular lymphoma that functioned by sustaining cell survival. 18, 19 Comparison of the sequence of E1B 19K and BCL-2 revealed a low level of homology of questionable significance, although an extensive mutational analysis of conserved residues in the E1B 19K protein indicated that this limited conservation was significant for E1B 19K protein function. 11 This prompted us to test for functional complementation of BCL-2 for E1B 19K in infection and epithelial cell oncogenesis.
At this point in July 1991, I contacted Stan Korsmeyer for the first time, to tell him that we thought that the E1B 19K protein functioned to inhibit apoptosis as a viral homologue of BCL-2, and we began a collaboration to test this hypothesis. This was the beginning of a long relationship that I will always cherish. We were able to demonstrate that BCL-2 expression was comparable to E1B 19K expression in rescuing cells from apoptosis induced by E1A and in the cooperation with E1A to induce immortalization of epithelial cells. 10 Although BCL-2 and E1B 19K are substantially less efficient at immortalization with E1A than direct inhibition of p53, this is because they only block the apoptosis function and not the cell cycle arrest function of p53. 20, 21 The immortal clones that arise from E1A plus either BCL-2 or E1B 19K are likely escape mutants that additionally overcome the p53-mediated cell cycle arrest function. BCL-2 also blocked apoptosis induced by p53 as did E1B 19K, and functionally complemented an E1B 19K adenovirus deletion mutant allowing sustained virus replication without apoptosis. 17, [20] [21] [22] These findings helped to demonstrate the comparable function of viral and cellular BCL-2 family members, thus crystallizing the central role of apoptosis in viral pathogenesis and in epithelial oncogenesis. 23 We now know there are subtle but important differences in the mechanisms by which E1B 19K and BCL-2 inhibit apoptosis in the BCL-2 associated X-protein (BAX) and BCL-2 antagonist/killer (BAK) pathway that are likely related to their heritage as viral versus cellular proteins.
Discussion E1B 19K blocks apoptosis by binding to and inhibiting BAX and BAK
To address the molecular mechanism by which the E1B 19K protein inhibited apoptosis, we performed a yeast two-hybrid screen to identify cellular E1B 19K interacting proteins. We identified BAX, 24 a protein that had been identified as a proapoptotic BCL-2 interacting protein in the Korsmeyer laboratory 25 ; natural born killer/BCL-2-interacting killer/BIKlike killer (NBK/BIK/BLK), a proapoptotic protein and the first BH3-only protein to be identified 26 ; and lamin A, which is involved in localization of E1B 19K to the nuclear envelope. 27 Other groups identified proapoptotic BAK as an E1B 19K and BCL-2 interacting protein [28] [29] [30] and there are a number of other joint E1B 19K/BCL-2 interacting proteins that remain poorly characterized. 31 These and other findings revealed that the BCL-2 family of proteins consists of proapoptotic and antiapoptotic members that are regulated by functional antagonism through protein-protein interactions. 32, 33 Binding specificity between the BH3 of one and recipient hydrophobic binding pocket of another BCL-2 family member largely regulates these protein interactions. 34, 35 E1B 19K preferentially inhibits activated BAX and BAK As our understanding of these protein-protein interactions among BCL-2 family members evolved, some interesting distinctions between E1B 19K and BCL-2 were uncovered: E1B 19K primarily functions as a BAX and BAK antagonist, whereas BCL-2 is more commonly associated with inhibition of BH3 -only proteins upstream of BAX and BAK. 23 With the exception of NBK/BIK/BLK, the E1B 19K protein does not bind any of the other BH3-only proteins examined so far that are known to bind BCL-2. The clearest example is the BH3-only protein BID, which binds and is inhibited by BCL-2 36-40 whereas E1B 19K does not bind or inhibit BID, but rather binds and inhibits activated BAX and BAK downstream of BID. [41] [42] [43] The BH3 of BAX is sufficient for E1B 19K protein interaction suggesting that E1B 19K acts as a BH3 receptor in cells following a change in the conformation of BAX that exposes the BH3 binding domain. 23, 24 Whether BAX and/or BAK are inhibited by E1B 19K depends on the specific apoptotic pathway.
E1B 19K inhibits BAX and BAK in death receptor-mediated apoptosis
In death receptor signaling of apoptosis, caspase-8 cleaves BID to active tBID that binds to and conformationally activates both BAX and BAK. This change in the conformation of BAX is associated with its translocation from the cytosol to mitochondrial membranes where BAK is already localized. Joint BAX and BAK activation causes BAX-BAK complex formation and oligomerization that renders the outer mitochondrial membrane permeable, causing the release of cytochrome c and second mitochondria-derived activator of caspase/Direct IAP binding protein with low pI that stimulate caspase-9 and -3 activation producing apoptosis. E1B 19K binds BAX and BAK following their conformational activation by tBID, which blocks their oligomerization, the release of proapoptotic mitochondrial proteins, caspase activation, and apoptosis. [41] [42] [43] Interestingly, E1B 19K expression in infected cells does not block caspase-8 activation upstream of BAX and BAK. Rather, E1B 19K interrupts the processing of caspase-9 allowing its cleavage by caspase-8 but not by caspase-3, because caspase-3 is downstream of BAX and BAK. 41 These events all occur under the physiological conditions of productive adenovirus infection rendering infected cells resistant to death receptor-mediated apoptosis, a critically important antiviral immune surveillance mechanism (Figure 1 ).
Apoptosis induced by viral infection is blocked primarily by E1B 19K inhibiting BAK
In infected cells where the death stimulus is E1A expression, BAK is preferentially activated, and E1B 19K binds BAK thereby preventing BAX activation, BAX-BAK complex formation and oligomerization, the release of proapoptotic mitochondrial proteins, caspase activation and apoptosis. 44 In the absence of BAK, however, BAX can functionally substitute, again creating the necessity for E1B 19K to inhibit both BAX and BAK (Figure 1 ). Cells that lack both BAX and BAK but not BAX or BAK are resistant to apoptosis induced by death receptor signaling and also to E1A during productive virus infection. Thus, complete complementation of an E1B 19K deletion mutant is achieved by deficiency in both BAX and BAK (Figure 2) . 44, 45 BAX and BAK are the essential core proapoptotic regulators in cells, and viruses have apparently evolved antiapoptotic functions that target this pivotal chokepoint in apoptosis signal transduction to provide the infected cell with a broad and robust defect in apoptosis. Indeed, adenovirus is not the only virus family to encode a BAX and BAK antagonist. Poxviruses and herpesviruses have since been found to encode BAX and/or BAK BH3-interacting and inhibitory proteins [46] [47] [48] [49] [50] [51] [52] some of which are BCL-2 homologs, and some not. Still other viruses encode BCL-2 homologs whose mechanism of action has yet to be determined. 23 The critical nature of inhibition of the apoptotic pathway by viruses is exemplified by the fact that many viruses also encode alternative and overlapping mechanisms to inhibit caspases upstream and downstream of BAX and BAK. 53 These antiapoptotic functions facilitate vibus replication, reactivation from latency, persistent infection, and immune evasion. 23 Thus, apoptosis is one component of the host's armamentarium to defeat viral infection. Viruses have, in turn, selectively evolved mechanisms to thwart this defense, and many of these mechanisms of virus/host interactions parallel those that occur between the tumor and host during oncogenesis.
E1A induces a DNA damage response that eliminates the BAK chaperone MCL-1
Once it was understood how apoptosis is inhibited by the E1B 19K protein in infected cells, we turned our attention to the mechanism by which E1A activated apoptosis. E1A sensitizes cells to death receptor-mediated apoptosis by preventing the NF-kB-dependent induction of the caspase-8 inhibitory protein c-FLIP, which may contribute to the sensitivity of infected cells to apoptosis in vivo. 54 Screening BCL-2 family members for functional modulation by E1A during productive virus infection in vitro revealed that E1A is responsible for inducing the complete elimination of the antiapoptotic BCL-2 family member myeloid cell leukemia sequence 1 (MCL-1). 55 MCL-1 elimination is required for apoptosis induction during infection, 55 similar to the role of MCL-1 in the apoptotic response to DNA damage. 56 E1A induces a DNA damage response, which accounts not only for the proteasomemediated degradation of MCL-1, but also for the accumulation of p53, which necessitates the inhibitory function of the E1B 55K protein. In healthy, uninfected cells, MCL-1 is bound to BAK, thereby suppressing the proapoptotic function of BAK. 55 Elimination of MCL-1 by E1A expression during infection is required for BAK release from MCL-1 and for BAK activation, but E1B 19K-BAK interaction blocks apoptosis. 55 Thus, E1B 19K can be thought of as a functional homolog of cellular MCL-1 (Figure 1 ). Infection with other DNA viruses may similarly provoke a DNA damage response and MCL-1 elimination, perhaps through induction of replication stress or owing to the presence of viral DNA. MCL-1 elimination in response to viral gene expression may explain the evolution of BAX and BAK inhibitors encoded by the viral genomes of DNA viruses.
Apoptosis regulation in oncogenesis and chemotherapeutic response
As predicted by the function of the viral oncogenes, epithelial tumorigenesis requires inhibition of the RB, p53, and BAX/ BAK pathways. E1A or c-MYC expression must be coupled to p53 inactivation for cellular immortalization, whereas tumorigenesis additionally requires inhibition of p53-independent apoptosis. 57 Activation of this p53-independent apoptotic pathway is linked to the induction of metabolic stress owing Figure 1 Regulation of apoptosis in adenovirus-infected cells. Adenovirus infection and E1 expression produces the three oncoproteins of the virus, E1A, E1B 55K and E1B 19K.
1,2 Yellow symbols indicate proapoptotic, blue symbols indicate antiapoptotic function, and faded symbols indicate failed signaling events. E1A induces a cellular DNA damage response that results in p53 accumulation, which can induce apoptosis through transcriptional upregulation of the BH3-only proteins PUMA and NOXA. 68 The E1B 55K protein binds p53 inhibiting its apoptotic and also growth arrest functions.
1,2 Induction of a DNA damage response by E1A also triggers the proteasome-mediated degradation of the BAK inhibitor MCL-1.
55 E1B 19K binds BAK and inhibits apoptosis. In the absence of BAK, BAX can functionally substitute for BAK and the E1B 19K protein can also bind and inhibit activated BAX. 44 In death receptor-mediated apoptosis where both BAX and BAK are activated, E1B 19K binds and inhibits both BAX and BAK. [41] [42] [43] Inhibition of this BAX and BAK pathway for apoptosis extends the survival of infected cells to the end of the replication cycle thereby facilitating virus production to ischemic conditions in the tumor microenvironment. 58 All tumors endure metabolic stress, either before acquisition of a blood supply during tumor establishment, or owing to episodic collapse of tumor vasculature in established tumors. Defects in apoptosis allow tumor cells to survive these intermittent periods of deprivation; however, these 'undead' tumor cells show signs of chromosome instability. 58 Thus, surviving metabolic stress in vivo may promote tumor growth, but it may be the survival of these damaged, chromosomally unstable cells that is the true cause of tumor progression (Figure 3) .
Deficiency in BAX and BAK or the gain-of-function of BCL-2 or E1B 19K promotes epithelial tumorigenesis in baby mouse kidney epithelial cells rendered immortal by RB and p53 pathway inactivation (immortal baby mouse kidney epithelial cells (iBMK) cells). 58 Interestingly, BCL-2 or E1B 19K have no additional tumor-promoting activity in the absence of BAX and BAK. 58 This genetic epistasis demonstrates that BCL-2 and E1B 19K function in the BAX and BAK apoptotic pathway to block apoptosis and promote the growth of epithelial carcinomas (Figure 3 ).
Identification of BIM as an epithelial tumor suppressor
To determine the apoptotic signaling events upstream of BAX and BAK that are responsible for tumor suppression, we screened immortal epithelial cells with defined deficiencies in BH3-only proteins for the ability to overcome the block to tumor growth. Whereas p53 upregulated modulator of apoptosis (PUMA), NOXA, and NBK/BIK/BLK deficiency does not enable tumorigenesis, BCL-2-like 11 (BIM) deficiency confers the capacity for tumor growth. 59 BIM is a potent BCL-2 antagonist in vivo, 60 and BIM inactivation is the mechanism of apoptosis inhibition by the MAP kinase pathway, which phosphorylates BIM causing its targeted degradation in proteasomes (Figure 3) . 59 BIM is also the determinant for taxane responsiveness; therefore, the loss or inactivation of BIM promotes not only tumor growth, but also resistance to taxane-mediated chemotherapy. 59 In tumors, where BIM function is compromised by activation of the MAP kinase pathway, proteasome inhibitors (Velcade, for example) rescue the therapeutic response to taxanes to promote tumor regression (Figure 3) . Thus determining the mechanism of apoptosis regulation and how common mutations found in human tumors disable apoptosis can produce a rational, tumor genotype specific approach to chemotherapy. 61 
Conclusions
These studies revealed that the proapoptotic BAX and BAK function as an antiviral response to limit virus replication, and that viral countermeasures include the evolution of BAX and BAK inhibitors encoded by viral BCL-2 homolog (v-BCL-2) proteins. This raises the possibility of therapeutic targeting of v-BCL-2 proteins as a means to induce apoptosis of infected (Figures 1 and 3) . Indeed, the ability of replicationcompetent mutant adenoviruses with defective antiapoptotic function to promote selective tumor cell killing is being exploited therapeutically. [62] [63] [64] [65] Many approaches for cancer therapy rely on inducing apoptosis of tumor cells, and understanding the mechanisms by which apoptosis is regulated is essential for therapeutic success. Deciphering the role for BIM in tumorigenesis and the response to taxanes is just one example of how defining the mechanisms by which mutations in human tumors prevent the apoptotic response can reveal a rational approach to chemotherapy. Similarly, determining the mechanisms by which chemotherapeutic drugs activate the apoptotic response in tumors and how this is impacted by the tumor genotype will be informative. 61 Many important issues related to apoptosis regulation in infected cells still remain to be addressed. For example, in virus-infected cells MCL-1 elimination is required but not sufficient for apoptosis indicating that there is a step missing in the activation of BAK, although tBID is apparently not involved. 55 It is also not known how MCL-1 releases BAK; however, one candidate is the BH3-only protein, NOXA that performs this function in other physiological settings. 66 Alternatively, NBK/BIK/BLK might be expected to play a role in virus-mediated apoptosis as it is targeted for inhibition by the E1B 19K protein. Our panel of BH3-only-deficient iBMK cells may be helpful in this regard. Finally, it is interesting to speculate that BAK may facilitate activation of BAX, but how BAX gets activated in the absence of BAK is not known.
In oncogenesis, defects in apoptosis in tumors allow cells to survive metabolic and other stresses that can lead to preservation of cells with chromosome instability. 58 We need to know how this chromosomal instability occurs and contributes to tumor progression. Although BIM plays a major role in suppression of epithelial tumorigenesis, it is not clear how BIM becomes activated and if it has a direct or indirect role in the activation of BAX and BAK. The BH3-only protein PUMA is induced by metabolic stress in vitro and in tumors in vivo but it is not required for tumor suppression, nor is NBK/ BIK/BLK or NOXA. 59 A more complete understanding of the different apoptotic stresses and the role of BH3-only proteins in regulating the BCL-2 family response in tumors will be informative. Furthermore, we need to identify alternate mechanisms for induction of cell death in tumors when apoptosis fails. Tumor cells can die by necrosis and mitotic catastrophe, and tumor cell survival may also be linked to autophagy. How tumor cells can be induced to die by alternative mechanisms and how this can be brought about therapeutically will be of great importance. 67 
Figure 3
Regulation of apoptosis in epithelial tumorigenesis. The red crossedout circles indicate deficiency mutations and the green arrows indicate gain-offunction mutations. Inactivation of the RB and p53 pathways renders primary mouse epithelial cells immortal, however, as they retain a robust p53-independent apoptotic response, they are not tumorigenic. 9, 57 In vivo tumor cell apoptosis induction is linked to ischemic conditions in the tumor microenvironment before angiogenesis that cause upregulation of HIF-1a, PUMA, and likely many other gene products. 58 PUMA is a BCL-2 antagonist that may contribute to apoptosis induction; however, PUMA deficiency alone is insufficient to enable tumor growth. Deficiency in BIM enables tumorigenesis, and BIM and BCL-2 are functionally antagonistic. 59 Upregulation of BCL-2 promotes apoptosis resistance and enables tumor growth. 59 Taxanes induce dramatic upregulation of BIM, which is required for taxane-mediated apoptosis. RAS or RAF activation in tumor cells causes ERK-dependent phosphorylation of BIM, which targets BIM for degradation by the ubiqutin/proteasome pathway. 59 RAS or RAF activation have no additional antiapoptotic activity in the absence of BIM demonstrating genetic epistasis, indicating that inactivation of BIM is the mechanism by which the MAP kinase pathway blocks apoptosis and produces resistance to taxanes. 59 Proteasome inhibitors such as Velcade block BIM degradation by the MAP kinase pathway and restore taxane-mediated apoptosis. BIM and BCL-2 act upstream of and require BAX and BAK function to regulate apoptosis. BIM cannot induce apoptosis in the absence of BAX and BAK, and BCL-2 has no tumorigenic activity in BAX and BAK deficient cells. 58 This genetic epistasis demonstrates that BIM and BCL-2 function in the BAX and BAK pathway. The v-BCL-2 E1B 19K binds and inhibits BAX and BAK and the tumorigenic activity of E1B 19K requires BAX and BAK. 58 Thus, inactivation of this BAX and BAK apoptotic pathway by any of these mechanisms results in tumorigenic epithelial cells that manifest chromosome instability that can promote tumor progression, and chemoresistance that can confound treatment response
